Abbisko Cayman (STU:8ZD) Debt-to-EBITDA : -0.08 (As of Dec. 2023)

View and export this data going back to 2022. Start your Free Trial

What is Abbisko Cayman Debt-to-EBITDA?

Debt-to-EBITDA measures a company's ability to pay off its debt.

Abbisko Cayman's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was €1.36 Mil. Abbisko Cayman's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was €3.23 Mil. Abbisko Cayman's annualized EBITDA for the quarter that ended in Dec. 2023 was €-54.61 Mil. Abbisko Cayman's annualized Debt-to-EBITDA for the quarter that ended in Dec. 2023 was -0.08.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for Abbisko Cayman's Debt-to-EBITDA or its related term are showing as below:

STU:8ZD' s Debt-to-EBITDA Range Over the Past 10 Years
Min: -0.1 Med: -0.07 Max: -0.01
Current: -0.09

During the past 5 years, the highest Debt-to-EBITDA Ratio of Abbisko Cayman was -0.01. The lowest was -0.10. And the median was -0.07.

STU:8ZD's Debt-to-EBITDA is ranked worse than
100% of 277 companies
in the Biotechnology industry
Industry Median: 1.36 vs STU:8ZD: -0.09

Abbisko Cayman Debt-to-EBITDA Historical Data

The historical data trend for Abbisko Cayman's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Abbisko Cayman Debt-to-EBITDA Chart

Abbisko Cayman Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

Debt-to-EBITDA

-0.07

-0.01

-0.03

-0.10

-0.09

Abbisko Cayman Semi-Annual Data
	Dec19	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Debt-to-EBITDA	Get a 7-Day Free Trial			-0.02	-0.12	-0.09	-0.10	-0.08

Competitive Comparison of Abbisko Cayman's Debt-to-EBITDA

For the Biotechnology subindustry, Abbisko Cayman's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Abbisko Cayman's Debt-to-EBITDA Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Abbisko Cayman's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Abbisko Cayman's Debt-to-EBITDA falls into.

Abbisko Cayman Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

Abbisko Cayman's Debt-to-EBITDA for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-EBITDA	=	Total Debt			/	EBITDA
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	EBITDA
	=	(1.363	+	3.225)	/	-52.783
	=	-0.09

Abbisko Cayman's annualized Debt-to-EBITDA for the quarter that ended in Dec. 2023 is calculated as

Debt-to-EBITDA	=	Total Debt			/	EBITDA
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	EBITDA
	=	(1.363	+	3.225)	/	-54.608
	=	-0.08

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is two times the quarterly (Dec. 2023) EBITDA data.

Abbisko Cayman (STU:8ZD) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.

Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

Abbisko Cayman Debt-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Abbisko Cayman's Debt-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.

Abbisko Cayman (STU:8ZD) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Abbisko Cayman Ltd (STU:8ZD) » Definitions » Debt-to-EBITDA

Comparable Companies

Traded in Other Exchanges

02256:Hong Kong

Address

Building 3, No. 898 Halei Road, Zhangjiang Hi-Tech Park, Pudong New Area, Shanghai, CHN

Website

https://www.abbisko.com

Abbisko Cayman Ltd is a investment holding company it operates through its subsidiaries which is a clinical-stage biopharmaceutical company dedicated to the discovery and development of innovative and differentiated small molecule oncology therapies. The company has only one business segment which is the development of innovative medicines.

Abbisko Cayman (STU:8ZD) Headlines

No Headlines